← Back to Blog

A technical overview of the delivery architecture underlying Phenotype Renovations™, prepared for prospective clients and interested readers.

Prepared by the Hephaestus Group, Integumentary Programmes.

The following summarizes, for interested field professionals outside of Furnetics, how our technologies achieve durable genetic alteration across the integument (such as fur, skin, and other textures) of an adult client. It is intended to answer a recurring question from prospective clients and to correct common misconceptions about how such work is performed. This article does not detail our clinical protocol omits proprietary details on which our results depend.

None of the underlying methods described here is unique to Furnetics. Researchers and practitioners will recognize that each extends a technique already established in the wider field. What is novel and proprietary is their integration, their adaptation to the tissues of the skin, and their execution at whole-body scale in adult humans.

The scale problem

Adult somatic alteration is frequently imagined as a cell-by-cell revision of existing tissue. This model is inaccurate and, taken literally, unworkable. The integument of an adult comprises tens of billions of keratinocytes, melanocytes, and follicular units, each subject to continuous turnover. Editing terminally differentiated cells in place would require near-complete coverage of a population that is, in most cases, already scheduled for replacement. The result would be a mosaic outcome: partial expression, uneven distribution, and a phenotype that regresses as edited cells are shed. Indeed, our early research work in the 2000's was primarily related to overcoming these specific problems.

The durability of a genetic alteration is, in principle, a solved problem. Ex vivo editing of hematopoietic stem cells now produces lifelong correction of inherited hemoglobin disorders from a single intervention, because the edited population continually renews the tissue it feeds. The unsolved problem (the one our group exists to address) is generalizing that logic from a single lineage to the entire integument. The limiting factors have been coverage and durability, not the genetic edit itself.

Source-directed editing (Wellspring™)

Furnetics does not target differentiated tissue. Under the Wellspring™ approach, alteration is directed at the stem and progenitor compartments that renew each tissue: the follicular bulge, the basal keratinocyte layer, and the melanocyte stem-cell niche. These compartments are small, numbering in the low thousands per region, and stable across the client’s lifespan. Between them they determine the character of the coat: the ratio of guard hair to underfur, pelage density and distribution, coloration and markings, and the extent of the vibrissal fields. Each of these is under known developmental control. Shaft identity (the distinction between coarse guard hair, awl, and the finer underfur) is set by the relative activity of EDAR, WNT/β-catenin, and BMP signaling within the follicular niche; follicle number and spacing by SHH-driven neogenesis and its reaction–diffusion patterning; pigmentation and its banding by the melanocortin axis, principally MC1R and the agouti signaling protein, acting on melanocyte output. Wellspring establishes durable set points across these pathways in the stem population rather than adjusting them transiently in the cells they produce. An edit established in these populations is propagated outward through normal turnover, so that successive generations of differentiated cells express the altered phenotype without further intervention. Coverage becomes a function of the tissue’s own renewal kinetics rather than of delivery volume, and the mosaic problem is resolved at its origin.

The approach is not novel in kind. Genetically corrected epidermal stem-cell grafts have regenerated functional skin across the majority of a patient’s body surface; ex vivo hematopoietic editing yields a corrected blood lineage for life from a single edited pool. Both demonstrate the same principle. Wellspring applies it across the several stem lineages of the skin at once, and in situ rather than by graft.

Delivery and tropism (Vesper™)

Our principal delivery challenge in the Morphic Series, for instance, is specificity. In vivo editing relies on established vehicles (recombinant AAV vectors and lipid nanoparticles) whose common limitation is tropism: they distribute broadly, engraft poorly in a chosen niche, and provoke an immune response sufficient to preclude repeat dosing. Directed evolution of capsid libraries has already produced vector variants with defined tissue preference. Vesper™ carriers extend this to compartment-level selectivity within the skin: each carrier is engineered per programme to recognize a niche by its surface signature (the LGR5+/CD34+/K15+ profile of the follicular bulge, or the integrin-α6-high fraction of the basal layer) through niche-homing peptides displayed on an engineered capsid loop, and to remain inert elsewhere; the lipid-nanoparticle payloads are directed to the same compartments by SORT-type formulation. Administration proceeds as a staged series across the Induction phase rather than as a single dose, and carrier generations are rotated so that each is withdrawn before adaptive immunity to it is established, preserving the option of subsequent administration.

Tolerance and the Residency (Prelude™)

Even a compartment-specific carrier presents novel antigens, and the delivery series must complete without sensitization. The stem-cell therapies now in clinical use depend on myeloablative conditioning: a genotoxic regimen that narrows eligibility considerably. The field is moving toward non-genotoxic, antibody-directed conditioning: antibody–drug conjugates raised against niche markers such as CD117 selectively vacate a stem-cell compartment without systemic toxicity, creating engraftment space for the edited population. Prelude™ adapts this to the follicular and melanocytic niches, and pairs it with transient control of humoral immunity to the carrier — pretreatment with an IgG-cleaving endopeptidase where pre-existing neutralizing titers are high, and co-administered empty-capsid decoys to absorb residual antibody — so that the staged Vesper series completes without sensitization. All of this precedes the introduction of any editing payload.

Because conditioning, delivery, and expression occur over an extended and closely monitored interval, Phenotype Renovations™ are conducted on a residential basis at the Sükhbaatar Square facility. The Residency is a clinical requirement rather than an amenity: it permits continuous monitoring of engraftment, immune status, and phenotypic expression across the full treatment arc, and it allows intervention before any deviation becomes established.

Our treatment arc and expression latency

Furnetics’ treatment comprises four phases: Induction (conditioning and delivery), Seeding (establishment of edited progenitor populations), Settling (phenotypic expression through turnover), and Consolidation (stabilization and monitoring). Visible change is confined almost entirely to Settling and proceeds at the rate of the relevant tissue’s turnover; it cannot be accelerated without compromising uniformity. The rate-limiting step is the hair cycle: an edited follicle expresses its new shaft identity only on re-entering anagen, and because human follicles cycle asynchronously rather than in coordinated waves, uniform conversion of a coat requires two to three full cycles. Epidermal and pigmentary turnover is faster (roughly six to eight weeks) so surface coloration generally stabilizes ahead of coat structure. Depending on the programme and the tissues involved, the interval from Induction to a stable result ranges from approximately 18 to 40 months, reflecting these separate clocks. Clients are advised during intake that early phenotype is partial and non-representative, and that formal assessment is deferred until Consolidation.

Monitoring and assessment

Progress is tracked against defined endpoints rather than client perception, which during Settling is an unreliable measure. Engraftment is confirmed by sampling of the target compartments; expression is assessed by distribution, density, uniformity, and (where a defined coat pattern has been specified) the registration and fidelity of that pattern across successive turnover cycles, including persistence through a complete molt; immune status is monitored throughout to detect carrier sensitization or conditioning drift; edited stem clones are tracked by lineage barcoding to confirm polyclonal reconstitution and exclude clonal dominance; and off-target activity is assessed against a predefined site panel. A result is classified as stable only when expression has persisted across a full renewal cycle following the final delivery, without regression and without further intervention. Outcomes short of this threshold are not represented to the client as final.

Regulatory concordance (Concordance™)

A common and consequential misconception is that a target phenotype is achieved by transferring the corresponding sequence from the selected template species. Direct transfer is ineffective: donor coding sequence introduced into a human genome lacks the regulatory context required for correct expression and typically produces dysregulation rather than the intended trait. For this reason the template library is at present confined to the Carnivora (principally Canidae, Felidae, and Mustelidae) whose coat architectures and pigmentation genetics are characterized well enough to model with confidence.

The relevant tools are current and well characterized. Base and prime editing install precise sequence changes without double-strand breaks. Epigenome editing establishes heritable transcriptional states (durable across cell division, and propagated through turnover) without altering the underlying DNA sequence at all. Multiplexed editing, the coordinated modification of many loci in a single programme, is routine in engineered cell lines and underlies the multiply-edited porcine organs now entering clinical transplantation, which carry dozens of coordinated genomic modifications. A single integumentary template resolves to a comparable package. This is on the order of forty to seventy coordinated sequence edits and regulatory reprogrammings, applied across the stem compartments as one defined set.

Concordance™ combines these to solve a specific failure mode. A donor cis-regulatory element depends on transcription factors expressed at donor-specific levels; in human cells those inputs are mistimed or absent, and the trait is silenced or misexpressed. Concordance therefore refactors the instruction onto human-compatible control rather than importing the donor regulatory sequence: a codon-adjusted coding sequence is placed under a synthetic promoter matched to the host follicular transcriptome, gated where required by dCas9-based synthetic circuits so that expression follows the tissue’s own cues. The resulting state is fixed with installed CpG methylation and H3K9me3 marks, which render it heritable through cell division and therefore propagated through turnover alongside the edit. The phenotype is reconstructed to function natively. This adaptation accounts for the greater part of our development timelines, and for the difference in outcome between our programmes and unregulated imitation.

Scope and limits

This overview concerns the integument only. Alteration of skeletal proportion and stance (including plantigrade-to-digitigrade conversion, which is a multi-disciplinary topic) together with tail structure, cranial and dental morphology, and comparable framework changes, is governed by entirely different constraints. Developmental morphology in particular is not achievable by any adult somatic procedure of the kind described here, and should not be inferred from the integumentary results above. Prospective clients receive a candid account of what is currently feasible, what remains investigational, and what falls outside our services, during consultation rather than in writing.

Candidate selection

For various reasons mentioned above, many applicants are unsuitable candidates. Screening assesses physiological tolerance for conditioning, immunological baseline (including pre-existing neutralizing titers to the carrier serotypes, which determine whether desensitization is required or the client is deferred) and the stability and specificity of the client’s stated objective. Objectives that are ambivalent, externally motivated, or subject to foreseeable revision are declined at intake. The arc is long, expression is progressive, and reversal is limited (and under-researched); suitability is therefore assessed as rigorously as feasibility.

Closing note

This summary is published to address recurring speculation and to set accurate expectations for prospective clients advised by their own independent genomic or medical experts. It describes the architecture of our approach and omits the proprietary elements (carrier design, conditioning regimen, and editing chemistry) that make it reproducible in our hands and not elsewhere. Detailed discussion is available under confidentiality during consultation.

Prepared by the Hephaestus Group, Integumentary Programmes.
Furnetics Unlimited Ltd. · Sükhbaatar Square, Ulaanbaatar